WP
IBIO icon

Woodline Partners’s iBio IBIO Stock Holding History

Woodline Partners’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
+1,776,547
New +$3.18M 0.01% 788

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Woodline Partners's IBIO Position: Q2 2026 in Review

Woodline Partners opened a new position in iBio (IBIO) in Q2 2026: 1,776,547 shares worth $3.11M. The stake represents 0.01% of the portfolio and ranks #788 among its holdings.

51 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Woodline Partners held 1,776,547 shares of iBio worth $3.11M as of Q2 2026.
  • iBio was a new Woodline Partners position in Q2 2026.
  • iBio made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #788 holding.
  • 51 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.